Two presentations presented findings from the investigation into the tragic death of the first participant in Capsida Biotherapeutics’ CAP-002 clinical trial at the American Society of Gene and Cell Therapy (ASGCT) Breakthroughs conference on November 13, and were reported today in STAT News. Sharing these findings marks an important and difficult moment for the STXBP1 community.
First and foremost, our thoughts remain with the child and their family. This loss has been felt deeply throughout our community, and we recognize that renewed discussion of the trial may bring difficult emotions for many families.
The first presentation from Ingo Helbig at Children’s Hospital of Philadelphia described researchers’ investigation which revealed that the CAP-002 therapy seemed to damage the lining of particular blood vessels in the brain called the post-capillary venules, which led to excess fluid entering the brain, brain swelling, and ultimately the death of the patient. It is important to know that the findings are sourced from the one sole patient dosed in the clinical trial. Nevertheless, these results are a critical step toward ensuring the safety of individuals who receive blood-brain barrier crossing gene therapies in the future.
The second presentation from Capsida explored why these findings were not seen in monkeys treated with CAP-002. Standard FDA safety studies found no problems when monkeys received doses twice the patient dose and evaluated months later. However, when researchers conducted additional studies using even higher doses of CAP-002 and looked at the brain just three days later, they found signs of brain swelling and one monkey died. These results suggest that looking at the brain early after treatment may be an important way to assess safety of future gene therapies designed to reach the brain.
CAP-002 represented an innovative approach to gene therapy, designed to overcome one of the greatest challenges in treating neurological disorders: delivering a therapy to enough cells in the brain to make a meaningful difference. The promise of this approach brought considerable hope to families affected by STXBP1.
The tragic outcome of the first patient's treatment underscored the complexity and risks associated with developing new therapies.
As a Foundation, we believe that carefully investigating and openly sharing what happened is essential. Understanding the findings will help researchers evaluate the challenges associated with this treatment approach and may contribute to the development of safer therapies in the future.
We understand both the hope that new therapies bring and the enormous responsibility involved in translating promising science into treatments for our children. Progress requires innovation, rigorous research, transparency, and an uncompromising commitment to patient safety.
We will continue collaborating with researchers, clinicians, and industry partners to advance promising approaches, learn from setbacks, and keep our community informed.
Our urgency to find treatments has not changed. Neither has our responsibility to pursue that goal thoughtfully, with the safety and well-being of individuals with STXBP1 at the center of everything we do.
“These findings are critical for the STXBP1 community as well as the broader field,” said Charlene Son Rigby, President of the STXBP1 Foundation. “Our families urgently need effective and safe therapies that change the course of this disease and make a real difference in our children’s lives. We’re hopeful this work will help make future gene therapies safer, and we’re deeply grateful to the research teams for their dedication.”
- The STXBP1 Foundation Team